Jagsonpal Pharma reported a significant 28% increase in Q4 EBITDA, reaching ₹111M compared to ₹87M last year. The company's margins also expanded, now standing at 17.3%, up from 14.9% in the same period last year.

Jagsonpal Pharma's Q4 profit increased by 33.1% year-on-year but dropped 20% quarter-on-quarter to ₹8.8 crore. The revenue also decreased by 12% quarter-on-quarter to ₹64.2 crore, leaving the stock at a level 31.4% below its 52-week high of ₹207.

Jagsonpal Pharma is proposing a significant dividend of 200% of the face value, amounting to Rs. 4 per share. If approved at their upcoming 47th Annual General Meeting, shareholders could receive this generous payout.

Jagsonpal Pharma has authorized a share buyback worth INR 40 crores at INR 250 per share, intended to optimize capital and enhance shareholder value.